Meeting
2018 ASCO Annual Meeting
Updated efficacy, safety, & PD-L1 status of patients with HR+, HER2- metastatic breast cancer administered abemaciclib plus pembrolizumab.
Authors
Sara M. Tolaney
Dana-Farber Cancer Institute, Boston, MA
Sara M. Tolaney , Peter Kabos , Maura N. Dickler , Luca Gianni , Valerie Jansen , Yi Lu , Suzanne Young , Hope S. Rugo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT02779751
Citation
J Clin Oncol 36, 2018 (suppl; abstr 1059)
DOI
10.1200/JCO.2018.36.15_suppl.1059
Abstract #
1059
Poster Bd #
140
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Phase I study combining pembrolizumab and aromatase inhibitor in patients with metastatic hormone receptor–positive breast cancer.
First Author: Xuan Ge
Poster
2020 ASCO Virtual Scientific Program
A phase Ib study of abemaciclib in combination with pembrolizumab for patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer (MBC) (NCT02779751): Interim results.
First Author: Hope S. Rugo
Poster
2020 ASCO Virtual Scientific Program
A phase Ib study of abemaciclib in combination with pembrolizumab for patients (pts) with stage IV Kirsten rat sarcoma mutant (KRAS-mut) or squamous non-small cell lung cancer (NSCLC) (NCT02779751): Interim results.
First Author: Jean-Louis Pujol
Poster
2022 ASCO Annual Meeting
Phase 3 ENABLAR-2 study to evaluate enobosarm and abemaciclib combination compared to estrogen-blocking agent for the second-line treatment of AR+, ER+, HER2- metastatic breast cancer in patients who previously received palbociclib and estrogen-blocking agent combination therapy.
First Author: Elgene Lim